Lancet. 1996 Dec 14;348(9042):1610-4.
Although surgery is the treatment of choice for rectal cancer, local recurrence is common even after apparently curative resection. We aimed to assess the role of postoperative radiotherapy in reducing rates of local recurrence, and improving disease-free and overall survival in patients with mobile Dukes' stage B and C rectal cancers.
We carried out a prospective, randomised trial of surgery alone (n = 235) versus surgery followed 4-6 weeks later by radiotherapy (n = 234), of 40 Gy in 20 fractions of 2 Gy over 4 weeks. The 469 patients, from 46 hospitals in the UK and the Republic of Ireland, were randomised between 1984 and 1989, and followed up for a minimum of 5 years or to death.
284 patients died, 145 of 235 allocated surgery alone and 139 of 234 allocated postoperative radiotherapy. The hazard ratio for overall survival was 0.84 (95% CI 0.65-1.07, p = 0.17). At 5 years' follow-up 79 patients who received surgery alone and 48 who received postoperative radiotherapy had had local recurrence (hazard ratio 0.54 [0.38-0.77], p = 0.001). The corresponding numbers with distant recurrence were 83 and 75 (hazard ratio 0.85 [0.63-1.114], p = 0.18). The hazard ratio for disease-free survival was 0.85 (0.65-1.08; p = 0.18). Radiotherapy was generally well tolerated; assessment of late events showed serious late bowel complications to be rare and not significantly increased after radiotherapy, even when this followed anterior resection.
Our results have provided further evidence of the ability of postoperative radiotherapy to delay and prevent local recurrence of rectal cancer. Although the local recurrence rate in the control group is in keeping with other multi-centre trials of the mid to late 1980s, it is undoubtedly higher than would be regarded as acceptable now. The combination of larger trials required to provide definitive answers on the impact that postoperative radiotherapy will have on survival.
尽管手术是直肠癌的首选治疗方法,但即使在进行了看似根治性的切除术后,局部复发仍很常见。我们旨在评估术后放疗在降低局部复发率、提高可移动的杜克B期和C期直肠癌患者无病生存率和总生存率方面的作用。
我们进行了一项前瞻性随机试验,比较单纯手术(n = 235)与手术4 - 6周后进行放疗(n = 234)的效果,放疗剂量为40 Gy,分20次,每次2 Gy,持续4周。这469名患者来自英国和爱尔兰共和国的46家医院,于1984年至1989年期间随机分组,并至少随访5年或直至死亡。
284名患者死亡,235名单纯接受手术治疗的患者中有145人死亡,234名接受术后放疗的患者中有139人死亡。总生存率的风险比为0.84(95%可信区间0.65 - 1.07,p = 0.17)。在5年随访时,235名单纯接受手术治疗的患者中有79人出现局部复发,234名接受术后放疗的患者中有48人出现局部复发(风险比0.54 [0.38 - 0.77],p = 0.001)。远处复发的相应人数分别为83人和75人(风险比0.85 [0.63 - 1.114],p = 0.18)。无病生存率的风险比为0.85(0.65 - 1.08;p = 0.18)。放疗一般耐受性良好;对晚期事件的评估显示,严重的晚期肠道并发症很少见,放疗后并未显著增加,即使是在前部切除术后也是如此。
我们的结果进一步证明了术后放疗能够延迟和预防直肠癌局部复发的能力。尽管对照组的局部复发率与20世纪80年代中后期的其他多中心试验结果相符,但无疑高于目前可接受的水平。需要进行更大规模的试验组合,以明确术后放疗对生存率的影响。